• Drugs Made In America Acquisition amended its Power Analytics Global merger on October 13, 2026, introducing a US$ 1.71 billion standalone valuation.
• The valuation falls from US$ 2.85 billion if Power Analytics fails to complete its APQC acquisition by November 1, 2026.
• Earlier triggers include termination of the APQC agreement or a written determination by the buyer’s independent directors that completion is impossible.
• A trigger removes the APQC closing requirement without creating termination rights; merger consideration remains payable entirely in shares at closing, without earnouts.
• Subsequent asset additions require another amendment, independent-director approval and a supplemental fairness opinion; total valuation cannot exceed US$ 2.85 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-111421), on October 21, 2026, and is solely responsible for the information contained therein.